证券代码：688366 证券简称：昊海生科 公告编号：2023-036 上海昊海生物科技股份有限公司 关于收到公司董事长提议回购公司股份的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海昊海生物科技股份有限公司（以下简称"公司"）于2023年8月17日收 到公司董事长侯永泰先生《关于提议上海昊海生物科技股份有限公司回购公司股 份的函》。提议内容主要如下： 一、提议人提议回购股份的原因和目的 侯永泰先生基于对公司未来持续发展的信心和对公司价值的认可，为了维护 广大投资者利益，增强投资者对公司的投资信心，同时促进公司稳定健康发展， 有效地将股东利益、公司利益和员工利益紧密结合在一起，提议公司通过集中竞 价交易方式进行股份回购。回购的股份将在未来合适时机全部用于员工持股计划 及/或股权激励计划。 二、提议人的提议内容 1、回购股份的种类：公司发行的人民币普通股（A股）股票。 2023年5月5日，公司完成2021年A股限制性股票激励计划第一个归属期第一 批次的归属登记，侯永泰先生归属股份数量为2.4260万股。除上 ...

上海昊海生物科技股份有限公司独立董事 关于第五届董事会第十三次会议相关事项的独立意见 我们作为上海昊海生物科技股份有限公司（以下简称"公司"）的独立董事， 根据《中华人民共和国公司法》等法律法规及《上海昊海生物科技股份有限公司 章程》的相关规定，基于独立、客观判断的原则，在认真审阅公司相关材料并听 取有关说明后，对公司第五届董事会第十三次会议审议的《关于公司 2023 年半 年度募集资金存放与实际使用情况的专项报告的议案》，发表如下独立意见： 上海昊海生物科技股份有限公司 2023 年 8 月 17 日 经审查，报告期内，公司募集资金的实际存放、使用情况与公司信息披露一 致，符合《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》及公 司《募集资金管理制度》的相关规定，公司不存在违规使用和存放募集资金的行 为，亦不存在改变或变相改变募集资金投资项目及损害股东利益的情况。我们同 意《关于公司 2023 年半年度募集资金存放与实际使用情况的专项报告的议案》。 独立董事：郭永清、苏治、赵磊、姜志宏、杨玉社 ...

证券代码：688366 证券简称：昊海生科 公告编号：2023-020 关于召开 2022 年度暨 2023 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、说明会类型 上海昊海生物科技股份有限公司（以下简称"公司"）已分别于 2023 年 3 月 25 日、2023 年 4 月 29 日在上海证券交易所网站（www.sse.com.cn）披露了《上 海昊海生物科技股份有限公司 2022 年年度报告》及《上海昊海生物科技股份有 限公司 2023 年第一季度报告》。为加强与投资者的深入交流，使投资者更加全面、 深入地了解公司情况，公司拟以视频录播和网络互动的方式召开 2022 年度暨 2023 年第一季度业绩说明会（以下简称"本次业绩说明会"），欢迎广大投资者积 极参与。公司现就本次业绩说明会提前向广大投资者征集相关问题，广泛听取投 资者的意见和建议。 会议召开时间：2023 年 5 月 12 日（星期五）上午 10:00-11:30 会议召开地点：上海证券交易所"上证路演中 ...

Financial Performance - The net profit attributable to shareholders for the first quarter was ¥9,613,418.44 after accounting for taxes and minority interests[6]. - The net profit attributable to shareholders of the listed company increased due to significant growth in operating income[33]. - Net profit attributable to shareholders of the listed company was ¥81,177,581.15, up 33.21% from ¥60,941,331.70 in the same period last year[41]. - The company reported a total profit of ¥112,095,668.59 for Q1 2023, compared to ¥69,806,178.33 in Q1 2022[48]. - Basic and diluted earnings per share both stood at ¥0.47, reflecting an increase driven by the growth in net profit attributable to shareholders[18][33]. - Basic earnings per share for Q1 2023 were ¥0.47, compared to ¥0.35 in the same period last year[41]. Revenue and Sales - Total operating revenue for Q1 2023 reached ¥611,252,893.65, representing a 29.06% increase compared to ¥473,617,820.88 in Q1 2022[48]. - The company experienced a significant increase in sales revenue from hyaluronic acid products due to the rapid recovery of the domestic medical beauty industry[33]. Assets and Liabilities - The total assets of the company as of March 31, 2023, amounted to ¥6,984,036,145.39, an increase from ¥6,892,398,253.88 as of December 31, 2022[12]. - The company's total assets increased by 1.33% to ¥6,984,036,145.39 compared to the end of the previous year[18]. - The total current assets increased to ¥3,660,348,521.72 from ¥3,532,115,166.92 year-over-year[12]. - The total liabilities increased to ¥1,087,042,005.92, up from ¥990,013,737.98, indicating a rise in financial obligations[18]. - The company's equity attributable to shareholders was ¥5,514,492,058.38, showing a slight decrease from the previous year's figure[18]. Cash Flow - Operating cash inflow from sales of goods and services reached ¥633,139,253.73, up from ¥511,144,187.98 in the same period last year[29]. - Net cash flow from operating activities was ¥79,930,962.49, a significant increase of 1,687.78% compared to ¥4,470,962.15 in Q1 2022[43]. - Cash flow from operating activities saw a substantial increase, attributed to the rise in operating income and previous inventory buildup[33]. - The company recorded a net cash flow from investing activities of ¥156,184,009.96, contrasting with a negative cash flow of -¥174,414,144.19 in Q1 2022[43]. Research and Development - Research and development expenses totaled ¥53,624,174.05, accounting for 8.77% of operating income, a decrease of 0.84 percentage points[18]. - Research and development expenses increased to ¥53,624,174.05 from ¥45,520,090.97, reflecting a focus on innovation[48]. Inventory and Receivables - The inventory value as of March 31, 2023, was ¥526,744,476.16, up from ¥485,238,796.88 in the previous year[12]. - The company’s accounts receivable increased to ¥415,730,029.31 from ¥381,526,389.55 year-over-year[12]. Investments - The company’s long-term equity investments decreased to ¥2,858,785.76 from ¥3,028,473.17 year-over-year[12]. - The company achieved an investment income of ¥517,071.28, down from ¥2,313,643.50 in Q1 2022[48]. Shareholder Information - The company reported a total of 8,369 ordinary shareholders at the end of the reporting period[34].

Financial Performance - The company's operating revenue for Q1 2023 reached RMB 611,252,893.65, representing a year-on-year increase of 29.06%[3] - Net profit attributable to shareholders was RMB 81,177,581.15, reflecting a growth of 33.21% compared to the same period last year[3] - Basic and diluted earnings per share were both RMB 0.47, marking a 34.29% increase from the previous year[3] - Total operating revenue for Q1 2023 reached RMB 611.25 million, a 29.1% increase from RMB 473.62 million in Q1 2022[18] - Net profit for Q1 2023 was RMB 84.95 million, up 33.9% compared to RMB 63.48 million in Q1 2022[19] - The company reported a total profit of RMB 112.10 million for Q1 2023, compared to RMB 69.81 million in Q1 2022, marking a 60.2% increase[18] Cash Flow - The net cash flow from operating activities increased significantly to RMB 79,930,962.49, a rise of 1,687.78% year-on-year[3] - Cash flow from operating activities for Q1 2023 was RMB 79.93 million, significantly higher than RMB 4.47 million in Q1 2022[22] - Cash flow from investing activities showed a net inflow of RMB 156.18 million in Q1 2023, compared to a net outflow of RMB 174.41 million in Q1 2022[21] - Cash flow from financing activities resulted in a net outflow of RMB 20.94 million in Q1 2023, an improvement from a net outflow of RMB 121.58 million in Q1 2022[23] Research and Development - Research and development expenses totaled RMB 53,624,174.05, accounting for 8.77% of operating revenue, a decrease of 0.84 percentage points year-on-year[3] - Research and development expenses increased to RMB 53.62 million in Q1 2023, representing a 17.8% rise from RMB 45.52 million in Q1 2022[18] Assets and Liabilities - Total assets at the end of the reporting period were RMB 6,984,036,145.39, up 1.33% from the end of the previous year[3] - Current assets totaled RMB 3,660,348,521.72, up from RMB 3,532,115,166.92 in the previous period, reflecting a growth of approximately 3.63%[14] - Cash and cash equivalents were RMB 2,602,235,451.20, compared to RMB 2,544,591,061.46 at the end of 2022, indicating an increase of about 2.56%[14] - Total liabilities reached RMB 1,087,042,005.92, up from RMB 990,013,737.98, marking an increase of around 9.83%[16] - Long-term borrowings rose significantly to RMB 137,254,152.36 from RMB 43,979,665.36, indicating a substantial increase[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,369[6] - The total number of shares held by the top ten shareholders accounted for 81.53% of the total shares, indicating a high concentration of ownership[10] Market and Product Development - The increase in operating revenue was driven by the recovery of the domestic medical beauty industry and the strong market acceptance of the third-generation hyaluronic acid product "Haimai" [5] - Sales revenue from artificial lenses also saw significant growth due to an increase in cataract surgeries nationwide[5] - The company has been actively promoting its orthokeratology lens products, contributing to revenue growth in that segment[5] - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[12]

Financial Performance - In 2022, the company's revenue reached RMB 2,103,438 thousand, an increase from RMB 1,750,116 thousand in 2021, representing a growth of approximately 20.1%[5] - The gross profit margin for 2022 was 68.8%, down from 72.0% in 2021, indicating a decrease in profitability[5] - The net profit attributable to shareholders was RMB 180,470 thousand in 2022, a decline of 48.7% compared to RMB 352,234 thousand in 2021[5] - The total assets as of December 31, 2022, amounted to RMB 6,892,399 thousand, slightly down from RMB 6,950,356 thousand in 2021[5] - The total liabilities increased to RMB 990,016 thousand in 2022 from RMB 890,070 thousand in 2021, resulting in a debt ratio of 14.4%[5] - The company issued a basic earnings per share of RMB 1.04 for 2022, compared to RMB 2.00 in 2021, reflecting a significant decrease[5] - The company reported a total revenue of RMB 2,103.44 million for 2022, representing an increase of RMB 353.32 million or 20.19% compared to the previous year[8] - Net profit attributable to shareholders was approximately RMB 180.47 million, while the net profit excluding non-recurring gains and losses was about RMB 158.75 million[6] Product Revenue Breakdown - The ophthalmic product line generated revenue of RMB 765.97 million, accounting for 36.42% of total revenue, with a year-on-year growth of 14.16%[9] - Revenue from medical beauty and wound care products reached RMB 744.34 million, representing 35.39% of total revenue, with a significant increase of 61.47% year-on-year[9] - The cataract product line generated revenue of RMB 366.00 million, a decrease of RMB 71.82 million or 16.40% year-on-year[13] - The revenue from myopia prevention and refractive correction products was RMB 377.01 million, an increase of RMB 160.77 million or 74.35% compared to the previous year[13] - The revenue from artificial lenses was RMB 277.15 million, a decrease of 16.26% year-on-year, primarily due to the termination of the distribution agreement with Zhuhai Xiangle Medical Equipment Co., Ltd.[13] - The revenue from other ophthalmic products was RMB 22.96 million during the reporting period[14] - The revenue breakdown for 2022 includes: Hyaluronic Acid at RMB 306.16 million (41.13% of total), hEGF at RMB 149.82 million (20.13%), and RF and laser equipment at RMB 288.36 million (38.74%), with respective growth rates of 27.91%, 17.73%, and 205.52%[21][23] Research and Development - Research and development efforts are being prioritized to innovate new products and technologies to meet market demands[1] - The company has completed clinical trials for its innovative hydrophobic aspheric intraocular lens products and is in the registration application phase[6] - The company aims to maintain its technological leadership by focusing on research and development, as well as collaboration with renowned research institutions[7] - In 2022, the company's R&D expenses amounted to RMB 182.19 million, an increase of RMB 14.59 million or 8.71% compared to the previous year, representing 8.66% of operating revenue[10] - The company has established a comprehensive R&D management system supported by a professional and high-quality R&D team, enhancing its competitive advantage in niche markets[179] - The company applied for 67 new patents and was granted 37 patents during the reporting period, bringing the total to 348 patents, including 100 invention patents, as of December 31, 2022[182] Strategic Initiatives - The company plans to focus on expanding its market presence and enhancing its product offerings in the coming years[1] - Strategic initiatives are being implemented to improve operational efficiency and drive future growth[1] - The company plans to enhance internal resource allocation and improve operational efficiency through the integration of acquired companies[7] - The company is exploring potential mergers and acquisitions to strengthen its competitive position in the industry[1] - The company aims to enhance its core competitiveness through the integration of acquired businesses and the optimization of its product lines[29] Market Position and Competitive Advantage - The company is the largest domestic producer of ophthalmic viscoelastic devices, holding a market share of 50.83% in 2021, up from 45.24% in 2020[11] - The company’s competitive advantages include a strong R&D platform for medical biomaterials and a comprehensive marketing strategy that enhances consumer experience and brand loyalty[22] - The company is expanding its market share and influence in the corneal reshaping lens market through exclusive distribution rights and product diversification[17] Employee and Management Information - The total employee compensation for the group in 2022 was approximately RMB 533.22 million, an increase of about RMB 118.84 million compared to RMB 414.38 million in 2021[40] - The company reported a total employee count of 1,990 as of December 31, 2022[83] - The company has established service contracts for directors and supervisors for a term of three years, subject to termination clauses[76] - The company has arranged appropriate liability insurance for its directors, supervisors, and senior management[80] Corporate Governance - The company has established a governance structure comprising the general meeting of shareholders, the board of directors, the supervisory committee, and the management team[116] - The board of directors consists of 11 members, including 4 executive directors, 2 non-executive directors, and 5 independent non-executive directors as of the end of the reporting period[117] - The company has established various corporate governance policies, including the Articles of Association, rules for shareholder meetings, and internal audit systems[131] - The company emphasizes gender diversity in recruitment, evaluating candidates based on professional qualifications and skills, opposing gender discrimination[129] Environmental, Social, and Governance (ESG) Initiatives - The company achieved a rating of AA in the ESG evaluation of A-share listed companies in China, ranking second in the industry[165] - The company has established an ESG governance structure, including a board of directors, an audit committee, and an ESG working group to ensure effective implementation of ESG strategies and risk management[171] - The company actively identifies and assesses climate change risks in accordance with TCFD guidelines to mitigate adverse impacts[199] - The company has established internal regulations for managing hazardous waste, air emissions, and wastewater to ensure compliance with environmental standards[198] Risks and Challenges - The company faces operational risks related to product quality and safety, which could lead to compensation claims and reputational damage if not managed properly[148] - Regulatory changes in China's healthcare system could increase compliance costs and reduce product demand if the company fails to adapt[149] - The company's growth is partially dependent on the increasing purchasing power and health awareness of Chinese residents, which could be affected by industry-wide slowdowns or public safety incidents[150]

五、报告期内主要经营情况 具体请参见本节"一、经营情况讨论与分析"。 (一) 主营业务分析 1. 利润表及现金流量表相关科目变动分析表 | --- | --- | --- | --- | --- | |----------------------------|------------------|------------------|-------|-----------------| | 科目 | 本期数 | 上年同期数 | | 变动比例（ % ） | | 营业收入 | 2,130,275,956.41 | 1,766,994,314.08 | | 20.56 | | 营业成本 | 660,760,785.64 | 492,921,606.15 | | 34.05 | | 销售费用 | 679,531,794.99 | 612,339,860.25 | | 10.97 | | 管理费用 | 402,266,581.59 | 282,517,274.17 | | 42.39 | | 财务费用 | -74,097,250.46 | -84,853,867.07 | | 不适用 | | 研发费用 | 182,19 ...

Financial Performance - The company recorded a total revenue of RMB 2,103.44 million for the year ended December 31, 2022, representing an increase of RMB 353.32 million or 20.19% compared to the previous year[2]. - The net profit attributable to shareholders was approximately RMB 180.47 million, a decrease of 48.76% compared to the previous year, while the net profit excluding non-recurring items was RMB 158.75 million, down 51.60%[2]. - Total revenue for the year 2022 reached RMB 2,103,438 thousand, a 20.2% increase from RMB 1,750,116 thousand in 2021[23]. - The company reported a profit attributable to ordinary equity holders of approximately RMB 180.47 million, a decrease of about RMB 171.76 million or 48.76% from RMB 352.23 million in 2021[85]. - The overall gross profit margin for the reporting period was 68.79%, down from 71.98% in 2021, primarily due to lower margins from newly acquired businesses[77]. Revenue Breakdown - Revenue from mainland China was RMB 1,699,078 thousand in 2022, up from RMB 1,542,592 thousand in 2021, representing a growth of 10.1%[23]. - The company’s revenue from ophthalmic products was RMB 765,969 thousand in 2022, compared to RMB 670,969 thousand in 2021, reflecting a growth of 14.2%[25]. - The company’s revenue from Europe increased significantly to RMB 140,814 thousand in 2022 from RMB 66,965 thousand in 2021, marking a growth of 109.5%[23]. - The company’s revenue from the United States rose to RMB 103,717 thousand in 2022, up from RMB 82,918 thousand in 2021, indicating a growth of 25.0%[23]. - The revenue from optical materials business was RMB 179.46 million, an increase of approximately RMB 18.12 million, with a growth rate of 11.23%[60]. Expenses and Costs - Research and development expenses amounted to approximately RMB 182.19 million, an increase of RMB 14.59 million or about 8.71% year-on-year, accounting for 8.66% of total revenue[2]. - Selling and distribution expenses increased to approximately RMB 679.53 million, up by about RMB 67.19 million or 10.97% from RMB 612.34 million in 2021[79]. - Administrative expenses rose to approximately RMB 405.30 million, an increase of about RMB 119.21 million or 41.67% compared to RMB 286.09 million in 2021[80]. - The cost of goods sold increased significantly to RMB 656,515,000 in 2022 from RMB 490,370,000 in 2021, representing a rise of about 33.9%[29]. Assets and Liabilities - Non-current assets increased to RMB 3,360.28 million from RMB 3,237.77 million in the previous year[6]. - Current assets decreased to RMB 3,532.12 million from RMB 3,712.59 million in the previous year[6]. - Total liabilities increased to RMB 990.02 million from RMB 890.07 million in the previous year[7]. - The total equity attributable to shareholders decreased to RMB 5,902.38 million from RMB 6,060.29 million in the previous year[8]. - The group’s total liabilities as of December 31, 2022, are approximately RMB 990.02 million, with a debt-to-asset ratio of 14.36%, an increase of 1.55 percentage points from 12.81% in 2021[91]. Dividends and Share Repurchase - The board proposed a final dividend of RMB 0.4 per share (tax included) for the year ended December 31, 2022[2]. - Proposed final dividend for 2022 is RMB 0.40 per share, totaling RMB 68,508,400, while the final dividend for 2021 was RMB 0.70 per share, totaling RMB 123,075,000[32][33]. - The company repurchased 1,692,100 H-shares during the year ended December 31, 2022, and canceled these shares on July 7, 2022[9]. - The company repurchased 2,859,000 H-shares at a total cost of approximately HKD 84,224,000, completing the cancellation of these shares on February 14, 2023[54]. Research and Development - The company completed clinical trials for its fourth-generation organic cross-linked hyaluronic acid products and is now in the registration application phase[2]. - The company is focused on expanding its ophthalmic and medical aesthetics product lines through innovation and R&D investment[57]. - The company is currently evaluating the impact of the new accounting standards on existing loan agreements, with no significant effects anticipated[21]. Market Position and Strategy - The company maintained its position as the largest producer of ophthalmic viscoelastic devices in China, with a market share of 50.83%[58]. - The company has exclusive distribution rights for high-end orthokeratology lenses in mainland China, enhancing market share and product variety[62]. - The company aims to enhance its core competitiveness through the integration of acquired enterprises and maximize operational efficiency in 2023[75]. - The company is leveraging its competitive advantages in medical biomaterials to lead the domestic micro-injection market for hyaluronic acid products[68]. Employee and Compensation - The total number of employees in the group as of December 31, 2022, is 1,990, with a breakdown of 701 in production, 344 in R&D, 599 in sales and marketing, 86 in finance, and 260 in administration[87]. - The total employee compensation for the reporting period is approximately RMB 533.22 million, an increase of about RMB 118.84 million from RMB 414.38 million in 2021, primarily due to the inclusion of Nanpeng Optics and the full-year performance of Ouhua Group[87].

2022 年第三季度报告 单位：元 币种：人民币 证券代码：688366 证券简称：昊海生科 上海昊海生物科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期 年初至报告 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|----------------------------------|------------------|----------------------- ...